These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24070629)

  • 1. Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.
    Sonia Angeline M; Sarkar A; Anand K; Ambasta RK; Kumar P
    Neuroscience; 2013 Dec; 254():379-94. PubMed ID: 24070629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat.
    Sonia Angeline M; Chaterjee P; Anand K; Ambasta RK; Kumar P
    Neuroscience; 2012 Sep; 220():291-301. PubMed ID: 22710069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
    Ulusoy GK; Celik T; Kayir H; Gürsoy M; Isik AT; Uzbay TI
    Brain Res Bull; 2011 Jul; 85(6):380-4. PubMed ID: 21600965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
    Thakur P; Nehru B
    Neuropharmacology; 2014 Apr; 79():190-200. PubMed ID: 24296154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Oleracein E, a Neuroprotective Tetrahydroisoquinoline, on Rotenone-Induced Parkinson's Disease Cell and Animal Models.
    Sun H; He X; Liu C; Li L; Zhou R; Jin T; Yue S; Feng D; Gong J; Sun J; Ji J; Xiang L
    ACS Chem Neurosci; 2017 Jan; 8(1):155-164. PubMed ID: 27731637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
    Hu LF; Lu M; Tiong CX; Dawe GS; Hu G; Bian JS
    Aging Cell; 2010 Apr; 9(2):135-46. PubMed ID: 20041858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
    Kandil EA; Sayed RH; Ahmed LA; Abd El Fattah MA; El-Sayeh BM
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1141-1150. PubMed ID: 31408200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone.
    Khadrawy YA; Salem AM; El-Shamy KA; Ahmed EK; Fadl NN; Hosny EN
    J Diet Suppl; 2017 Sep; 14(5):553-572. PubMed ID: 28301304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease.
    Balakrishnan R; Vijayraja D; Mohankumar T; Manimaran D; Ganesan P; Choi DK; Elangovan N
    J Chem Neuroanat; 2021 Mar; 112():101890. PubMed ID: 33220427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apilarnil exerts neuroprotective effects and alleviates motor dysfunction by rebalancing M1/M2 microglia polarization, regulating miR-155 and miR-124 expression in a rotenone-induced Parkinson's disease rat model.
    Salama RM; Darwish SF; Yehia R; Eissa N; Elmongy NF; Abd-Elgalil MM; Schaalan MF; El Wakeel SA
    Int Immunopharmacol; 2024 Aug; 137():112536. PubMed ID: 38909495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep disturbances in the rotenone animal model of Parkinson disease.
    García-García F; Ponce S; Brown R; Cussen V; Krueger JM
    Brain Res; 2005 May; 1042(2):160-8. PubMed ID: 15854587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective Effects of a Standardized Flavonoid Extract from Safflower against a Rotenone-Induced Rat Model of Parkinson's Disease.
    Ablat N; Lv D; Ren R; Xiaokaiti Y; Ma X; Zhao X; Sun Y; Lei H; Xu J; Ma Y; Qi X; Ye M; Xu F; Han H; Pu X
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27563865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotenone induces non-specific central nervous system and systemic toxicity.
    Lapointe N; St-Hilaire M; Martinoli MG; Blanchet J; Gould P; Rouillard C; Cicchetti F
    FASEB J; 2004 Apr; 18(6):717-9. PubMed ID: 14766796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of caloric vestibular stimulation in improvement of motor symptoms and inhibition of neuronal degeneration in rotenone model of Parkinson's disease - An experimental study.
    Thanalakshmi J; Archana R; Senthilkumar S; Shakila R; Pazhanivel N; Subhashini S
    Physiol Int; 2020 Oct; 107(3):390-405. PubMed ID: 33021954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease.
    Qin J; Wu M; Yu S; Gao X; Zhang J; Dong X; Ji J; Zhang Y; Zhou L; Zhang Q; Ding F
    Toxicol Lett; 2015 Nov; 238(3):70-82. PubMed ID: 26276080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.
    Ravenstijn PG; Merlini M; Hameetman M; Murray TK; Ward MA; Lewis H; Ball G; Mottart C; de Ville de Goyet C; Lemarchand T; van Belle K; O'Neill MJ; Danhof M; de Lange EC
    J Pharmacol Toxicol Methods; 2008; 57(2):114-30. PubMed ID: 18155613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.